It has been reported that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) repress tumor lymphangiogenesis in lung cancer via the JAK/STAT3 cascade [38]. Here, STAT3 is linked to lung carcinoma.